Skip to main content

Advertisement

SpringerLink
Log in

Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET–CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

We aimed to demonstrate whether PET–CT can replace bone marrow biopsy in detecting bone marrow involvement in subtypes of lymphoma. In addition, we aimed to also reveal whether there is a difference between the mean survival of patients with bone marrow involvement via PET–CT or biopsy. A total of 276 newly diagnosed lymphoma patients who underwent bone marrow biopsy and PET–CT prior to the treatment were scanned retrospectively. Bone marrow biopsy was used as the standard method to investigate the presence of bone marrow involvement in PET–CT. The relationship between bone marrow involvement and mean survival was compared using both methods. Out of the 276 patients, bone marrow involvement was detected with PET–CT and with biopsy, respectively in 56 patients (20.2%) and in 78 patients (28.2%). In terms of PET–CT’s accuracy with respect to revealing bone marrow involvement, the highest rates were achieved respectively in diffuse large B cell lymphoma (DLBCL) (87.4%) and Hodgkin lymphoma (HL) (77.7%). In both the PET–CT and bone marrow biopsy methods, Overall Survival (OS) was found to be significantly shorter in patients with involvement than in patients without involvement (P: 0.001). PET–CT may replace bone marrow (BM) biopsy in detecting the bone marrow involvement in aggressive lymphoma subtypes such as DLBCL and HL. The presence of BM involvement at the time of diagnosis in both PET–CT and BM biopsy is associated with poor prognosis, and OS is short in this group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059–3067. https://doi.org/10.1200/JCO.2013.54.8800

    Article  PubMed  PubMed Central  Google Scholar 

  3. Schaefer NG, Hany TF, Taverna C et al (2004) Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 232(3):823–829. https://doi.org/10.1148/radiol.2323030985

    Article  PubMed  Google Scholar 

  4. Menon NC, Buchanan JG (1979) Bilateral trephine bone marrow biopsies in hodgkin and non-hodgkin lymphoma. Pathology 11(1):53–57. https://doi.org/10.3109/00313027909063538

    Article  CAS  PubMed  Google Scholar 

  5. Wang J, Weiss LM, Chang KL et al (2002) Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 94(5):1522–1531. https://doi.org/10.1002/cncr.10364

    Article  PubMed  Google Scholar 

  6. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16(2):603–609. https://doi.org/10.1200/JCO.1998.16.2.603

    Article  CAS  PubMed  Google Scholar 

  7. Adams HJA, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RAJ, de Klerk JMH (2015) Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: ıncidence and relevance. Eur J Haemato 95(1):83–89. https://doi.org/10.1111/ejh.12483

    Article  CAS  Google Scholar 

  8. Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy—a review of UK data for 2004. Haematologica 91(9):1293–1294

    PubMed  Google Scholar 

  9. Adams HJA, Kwee TC, De Keizer B, Fijnheer R, De Klerk JMH, Nievelstein RAJ (2014) FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 41(3):565–574. https://doi.org/10.1007/s00259-013-2623-4

    Article  CAS  PubMed  Google Scholar 

  10. Moog F, Bangerter M, Diederichs CG et al (1998) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206(2):475–481. https://doi.org/10.1148/radiology.206.2.9457202

    Article  CAS  PubMed  Google Scholar 

  11. Sato M, Hiyama T, Kaito K, Hayashi Y, Okumura T (2009) Usefulness of F-18 FDG PET/CT in the assessment of disseminated Mycobacterium avium complex infection. Ann Nucl Med 23(8):757–762. https://doi.org/10.1007/s12149-009-0298-5

    Article  PubMed  Google Scholar 

  12. El-Galaly TC, D’Amore F, Mylam KJ et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30(36):4508–4514. https://doi.org/10.1200/JCO.2012.42.4036

    Article  PubMed  Google Scholar 

  13. O’Carroll DI, McKenna RW, Brunning RD (1976) Bone marrow manifestations of Hodgkin disease. Cancer 38(4):1717–1728. https://doi.org/10.1002/1097-0142(197610)38:4%3c1717:AID-CNCR2820380445%3e3.0.CO;2-9

    Article  PubMed  Google Scholar 

  14. Weiler-Sagie M, Kagna O, Dann EJ, Ben-Barak A, Israel O (2014) Characterizing bone marrow involvement in Hodgkin lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging 41(6):1133–1140. https://doi.org/10.1007/s00259-014-2706-x

    Article  PubMed  Google Scholar 

  15. Muzahir S, Mian M, Munir I et al (2012) Clinical utility of 18 F FDG-PET/CT in the detection of bone marrow disease in Hodgkin lymphoma. Br J Radiol 85(1016):490–496. https://doi.org/10.1259/bjr/29583493

    Article  Google Scholar 

  16. Pelosi E, Penna D, Douroukas A et al (2011) Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 55(4):469–475

    CAS  PubMed  Google Scholar 

  17. Eichenauer DA, Engert A, Federico M, Illidge T, Hutchings M, Ladetto M (2014) Clinical practice guidelines Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up † clinical practice guidelines. 25:1–6. https://doi.org/10.1093/annonc/mdu181

  18. Chung R, Lai R, Wei P et al (2019) Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the ınternational prognostic ındex. Blood J Am Soc Hematol 110(4):1278–1283. https://doi.org/10.1182/blood-2007-01-070300

    Article  CAS  Google Scholar 

  19. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S (2006) The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 76(6):473–480. https://doi.org/10.1111/j.1600-0609.2006.00644.x

    Article  PubMed  Google Scholar 

  20. Pakos EE, Fotopoulos AD, Ioannidis JPA (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46(6):958–963

    PubMed  Google Scholar 

  21. Teagle AR, Barton H, Charles-Edwards E, Dizdarevic S, Chevassut T (2017) Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy. Acta Radiol 58(12):1476–1484. https://doi.org/10.1177/0284185117701305

    Article  PubMed  Google Scholar 

  22. Berthet L, Cochet A, Kanoun S et al (2013) In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54(8):1244–1250. https://doi.org/10.2967/jnumed.112.114710

    Article  CAS  PubMed  Google Scholar 

  23. Khan AB, Barrington SF, Mikhaeel NG et al (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122(1):61–67. https://doi.org/10.1182/blood-2012-12-473389

    Article  CAS  PubMed  Google Scholar 

  24. Canioni D, Brice P, Lepage E et al (2004) Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d’Etude des Lymphomes Folliculaires. Br J Haematol 126(3):364–371. https://doi.org/10.1111/j.1365-2141.2004.05046.x

    Article  PubMed  Google Scholar 

  25. Lee EYP, Gill H, Wang Y, Kwong YL, Khong PL (2015) Bone marrow uptake of indolent non-Hodgkin lymphoma on PET/CT with histopathological correlation. Nucl Med Commun 36(10):1035–1041. https://doi.org/10.1097/MNM.0000000000000361

    Article  CAS  PubMed  Google Scholar 

  26. Adams HJA, Nievelstein RAJ, Kwee TC (2015) Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev 29(6):417–425. https://doi.org/10.1016/j.blre.2015.06.003

    Article  PubMed  Google Scholar 

  27. Luminari S, Biasoli I, Arcaini L et al (2013) The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 24(8):2108–2112. https://doi.org/10.1093/annonc/mdt137

    Article  CAS  PubMed  Google Scholar 

  28. Le Dortz L, De Guibert S, Bayat S et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37(12):2307–2314. https://doi.org/10.1007/s00259-010-1539-5

    Article  PubMed  Google Scholar 

  29. Hosein PJ, Pastorini VH, Paes FM et al (2011) Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 86(10):841–845. https://doi.org/10.1002/ajh.22126

    Article  PubMed  Google Scholar 

  30. Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F et al (2015) Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol 33(4):151–158. https://doi.org/10.1002/hon.2181

    Article  CAS  PubMed  Google Scholar 

  31. Muslimani AA, Farag HL, Francis S et al (2008) The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol Cancer Clin Trials 31(5):409–412. https://doi.org/10.1097/COC.0b013e318168d90b

    Article  Google Scholar 

  32. Jerusalem G, Beguin Y, Najjar F et al (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin lymphoma (NHL). Ann Oncol Off J Eur Soc Med Oncol 12(6):825–830. https://doi.org/10.1023/a:1011169332265

    Article  CAS  Google Scholar 

  33. Okada J, Yoshikawa K, Imazeki K et al (1991) The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 32(4):686–691

    CAS  PubMed  Google Scholar 

  34. Sovani V, Harvey C, Haynes AP, McMillan AK, Clark DM, O’Connor SR (2014) Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J Clin Pathol 67(5):389–395. https://doi.org/10.1136/jclinpath-2013-201520

    Article  PubMed  Google Scholar 

  35. Carr R, Barrington SF, Madan B et al (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 91(9):3340–3346

    Article  CAS  PubMed  Google Scholar 

  36. Coller BS, Chabner BA, Gralnick HR (1977) Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol 3:105–119. https://doi.org/10.1002/ajh.2830030201

    Article  CAS  PubMed  Google Scholar 

  37. Freudenberg LS, Antoch G, Schütt P et al (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31(3):325–329. https://doi.org/10.1007/s00259-003-1375-y

    Article  CAS  PubMed  Google Scholar 

  38. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS (2009) Comparison of CT, PET, and PET/CT for staging of patients with indolent non-hodgkin lymphoma. Mol Imaging Biol 11(4):269–274. https://doi.org/10.1007/s11307-009-0200-9

    Article  PubMed  PubMed Central  Google Scholar 

  39. El Karak F, Bou-Orm IR, Ghosn M et al (2017) PET/CT scanner and bone marrow biopsy in detection of bone marrow ınvolvement in diffuse large B-cell lymphoma. PLoS ONE 12(1):2–9. https://doi.org/10.1371/journal.pone.0170299

    Article  CAS  Google Scholar 

  40. Adams HJA, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RAJ, de Klerk JMH (2014) Bone marrow 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol 89(7):726–731. https://doi.org/10.1002/ajh.23730

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

There is no source of financial support or funding.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Antalya Training and Research Hospital, 07100, Antalya, Turkey

    Mesut Göçer & Erdal Kurtoğlu

Authors
  1. Mesut Göçer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erdal Kurtoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mesut Göçer.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest or relevant financial relationships related to this study.

Ethical Statement

The study protocol received institutional review board approval and all patient’s personal data have been secured.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Göçer, M., Kurtoğlu, E. Comparison of Bone Marrow Involvement with Bone Marrow Biopsy and PET–CT and Evaluation of Any Effects on Survival in Patients Diagnosed with Hodgkin and Non-Hodgkin Lymphoma. Indian J Hematol Blood Transfus 37, 52–59 (2021). https://doi.org/10.1007/s12288-020-01284-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-020-01284-x

Keywords

Search

Navigation